您的位置：首页 > 产品中心 > 108605-62-5， Leflunomide Related Compound B
Leflunomide Related Compound B
| 产品编号： | 4119798 |
| 规格： | pharmaceutical secondary standard, certified reference material |
| CAS NO： | 108605-62-5 |
| 包装规格： | 50 mg |
| 产品类别： | 进口试剂 |
| 品牌： | Supelco |
| 优惠价： | 立即咨询 |
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4119798 | 50 mg | 7340 |
产品别名
108605-62-5
Leflunomide Related Compound B
2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C12H9F3N2O2 |
| Molecular weight | 270.21 |
| MDL number | MFCD00910058 |
| General description【一般描述】 | Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards |
| Analysis Note【分析说明】 | These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. |
| Other Notes【其他说明】 | This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. |
产品性质
| grade【等级】 | certified reference material pharmaceutical secondary standard |
| CofA | current certificate can be downloaded |
| packaging【包装】 | pkg of 50 mg |
| application(s) | pharmaceutical |
| pharmacopeia traceability【药典可追溯性】 | traceable to USP 1357056 |
| storage temp.【储存温度】 | 2-8℃ |
| SMILES string | O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1 |
| InChI | 1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7- |
| InChI key | UTNUDOFZCWSZMS-YFHOEESVSA-N |
安全信息
| Pictograms【象形图】 | GHS06 |
| Signal word【警示用语：】 | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P264 - P270 - P301 + P310 - P405 - P501 |
| Hazard Classifications【危险分类】 | Acute Tox. 3 Oral |
| Storage Class Code【储存分类代码】 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
